-
d-Limonene +Radiation +Platinum Based Chemo for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma
Recruiting
More
This study explores the safety of d-limonene, a commercially-available dietary supplement
(food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by
patients with head and neck cancer as a side effect of their anti-cancer treatment.
Lead Sponsor
Stanford Investigators
View full details
-
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Not Recruiting
More
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous
cell). Specialized radiation therapy that delivers a high dose of radiation directly to the
tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in
chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a
monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. The purpose of this study is to compare the usual treatment (radiation therapy with
cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy,
and using the usual treatment plus an immunotherapy drug, atezolizumab.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery
Not Recruiting
More
The purpose of this study is determine salivary gland disposition of d-limonene, the primary
component in citrus peel and a common dietary supplement.
Salivary gland tissue and saliva will be collected to determine concentration of d-limonene
and its metabolites in these tissues.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
View full details
-
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Recruiting
More
This phase II/III trial studies how well a reduced dose of radiation therapy works with
nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive
oropharyngeal cancer that is early in its growth and may not have spread to other parts of
the body (early-stage), and is not associated with smoking. Radiation therapy uses
high-energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as
cisplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with
monoclonal antibodies, such as nivolumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is
being done to see if a reduced dose of radiation therapy and nivolumab works as well as
standard dose radiation therapy and cisplatin in treating patients with oropharyngeal cancer.
Stanford Investigators
View full details
-
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet
known if giving radiation therapy to the head is effective in preventing CNS metastases in
patients who have stage III non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head
works in preventing CNS metastases in patients who have been previously treated for stage III
non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Derek Huang, 6507250203.
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an
effective treatment for extensive stage small cell lung cancer.
PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain
works when given with or without radiation therapy to other areas of the body in treating
patients with extensive stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
Not Recruiting
More
This phase II trial is studying how well giving bevacizumab together with cisplatin,
radiation therapy, and fluorouracil works in treating patients with stage IIB, stage III,
stage IVA, or stage IVB nasopharyngeal cancer. Monoclonal antibodies, such as bevacizumab,
can block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Bevacizumab may also stop the growth of nasopharyngeal cancer by blocking blood flow to the
tumor. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab
together with chemotherapy and radiation therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Derek Huang, 6507250203.
Stanford Investigators
View full details
-
Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Not Recruiting
More
This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and
fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy
works in treating patients with advanced nasopharyngeal cancer. Drugs used in chemotherapy,
such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy
uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a
high dose of radiation directly to the tumor may kill more tumor cells and cause less damage
to normal tissue. Giving combination chemotherapy together with radiation therapy may kill
more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Cisplatin may also make tumor
cells more sensitive to radiation therapy. Monoclonal antibodies, such as cetuximab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Giving radiation therapy and cisplatin together with cetuximab may kill more tumor cells. It
is not yet known whether radiation therapy and cisplatin are more effective with or without
cetuximab in treating head and neck cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy, cisplatin, and
cetuximab to see how well they work compared to radiation therapy and cisplatin in treating
patients with stage III or stage IV head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Trevor Elizabeth Krakow, 6507254777.
Stanford Investigators
View full details
-
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Recruiting
More
The purpose of this study is to identify and confirm new blood and tissue markers for
prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has
been shown to increase the risk of tumor spread and enhance tumor resistance to the standard
treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently
identified several proteins or markers in the blood and in tumors (including osteopontin,
lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that
may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Lead Sponsor
Stanford Investigators
View full details
-
Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer
Not Recruiting
More
Endoscopy is a standard part of the evaluation of patients with head and neck cancer used for
determining the extent of tumor involvement. However, not all areas involved by tumor are
apparent visually. Preliminary results indicate that compared with normal tissues, tumors
have abnormal levels of capillary oxygenation. The purpose of this study is to determine the
ability of non-pulsatile visible light tissue oxygen monitoring to differentiate normal and
tumor tissue based on capillary oxygenation during endoscopy Should this be possible, this
method could be used to mark tumor extent and invasion, even when that invasion is up to 5mm
blow the tissue surface.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peter Maxim, 6507243018.
Lead Sponsor
Stanford Investigators
View full details
-
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Recruiting
More
The purpose of this study is to measure the levels of serum proteins and other biomarkers in
cancer patients and in patients suspected of having cancer. We believe that some of these
markers may be useful for confirming the diagnosis or for selecting patients for specific
types of cancer therapies. These markers may also help to predict response to therapy,
relapse after therapy, and survival after therapy.
Lead Sponsor
Stanford Investigators
View full details
-
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
Not Recruiting
More
This study has two primary objectives. The first objective is to determine the maximal
tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with
inoperable malignant lung tumors. Once the MTD is established, the second objective is to
determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and
radiographic responses.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of AG013 (genetically
modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the
ability of AG013 to attenuate the course and severity of oral mucositis (OM) in subjects
receiving induction chemotherapy for the treatment of head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
Not Recruiting
More
The purpose of this study is to determine the value of novel non-invasive medical imaging
methods for detecting the spread of head and neck squamous cell carcinoma to the lymph nodes
in the neck by comparing their results to findings at the time of surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 6504986184.
Lead Sponsor
Stanford Investigators
View full details
-
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast
Not Recruiting
More
To determine the ability of magnetic resonance lymphangiography using conventional gadolinium
injected directly into the tumor site and PET scan in detecting microscopic nodal metastasis
in patients with newly diagnosed H&N cancers
Stanford is currently not accepting patients for this trial.
For more information, please contact Bill Loo, 6507367143.
Lead Sponsor
Stanford Investigators
View full details
-
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to assess the short and long-term outcomes after CyberKnife
stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who
are medically inoperable.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
Not Recruiting
More
To see if a limited sampling of tumor tissue from human subjects is a feasible way to gather
adequate tissue for cancer stem cell quantification.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors.
Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
antibodies, such as cetuximab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. It is not yet known whether radiation therapy is more
effective with cisplatin or cetuximab in treating oropharyngeal cancer.
PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to
see how well it works in treating patients with oropharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
Not Recruiting
More
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy
and radiation therapy. It is not yet known whether Manuka honey is more effective than
standard care in preventing pain.
PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it
works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation
therapy for lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Surgery with or without internal radiation therapy may be an effective treatment
for non-small cell lung cancer. Internal radiation uses radioactive material placed directly
into or near a tumor to kill tumor cells. Stereotactic body radiation therapy may be able to
send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known
whether stereotactic body radiation therapy is more effective than surgery with or without
internal radiation therapy in treating non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well surgery with or without
internal radiation therapy works compared with stereotactic body radiation therapy in
treating patients with high-risk stage IA or stage IB non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Not Recruiting
More
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This randomized phase II/III trial is studying how well image-guided radiosurgery or
stereotactic body radiation therapy works and compares it to external-beam radiation therapy
in treating patients with localized spine metastasis.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alifia Hasan, 650-725-1723.
Stanford Investigators
View full details
-
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Not Recruiting
More
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to
help focus thin beams of radiation directly on the tumor, and giving radiation therapy in
higher doses over a shorter period of time, may kill more tumor cells and have fewer side
effects. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. It is not yet known whether radiation
therapy is more effective when given alone or together with cetuximab in treating patients
with head and neck cancer that has been removed by surgery.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it
works compared with radiation therapy given together with cetuximab in treating patients who
have undergone surgery for locally advanced head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-723-1423.
Stanford Investigators
View full details
-
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether giving chemotherapy together with radiation therapy is more effective with or without
vandetanib in treating patients with head and neck cancer.
PURPOSE: This randomized phase II trial is studying giving chemotherapy together with
radiation therapy to see how well it works compared with giving chemotherapy and radiation
therapy together with vandetanib in treating patients with high-risk stage III or stage IV
head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Brindha Bavan, 6507254777.
Stanford Investigators
View full details
-
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
Not Recruiting
More
The purpose of this study is to assess how well this particular combination of chemotherapy,
radiation and surgery works to help people with locally advanced lung cancer, how well PET
scans indicates whether someone has responded to chemotherapy and radiation, and gene
expression patterns related to outcomes in patients with locally advanced lung cancer who
receive this treatment regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. It is not yet known whether
radiation therapy is more effective when given together with chemotherapy or alone after
surgery in treating salivary gland tumors.
PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without
chemotherapy to see how well it works in treating patients with high-risk malignant salivary
gland tumors that have been removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
Not Recruiting
More
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation
therapy. It is not yet known if memantine is effective in preventing side effects caused by
whole-brain radiation therapy.
PURPOSE: This randomized phase III trial is studying memantine to see how well it works
compared to a placebo in preventing side effects caused by whole-brain radiation therapy in
patients with brain metastases from solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leslie Modlin, 6507238843.
Stanford Investigators
View full details
-
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Not Recruiting
More
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the
standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy
with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many
patients are poor operative candidates or decline surgery.
This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool
to produce therapeutically useful computed tomography (CT) scans, using standard
water-soluble iodinated compounds as the contrast agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
-
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Not Recruiting
More
This is a single-center cross-sectional imaging and correlative biomarker study in patients
with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with
unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment
and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1
treatment prior to tumor resection or radiation. Blood sampling and tissue biopsies will be
collected from both cohorts and both cohorts will undergo two whole body PET(Positron
Emission Tomography)/CT(Computed Tomography) imaging with [18F]F-AraG. First scan prior to
initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment in
Cohort 1 and prior to tumor resection or radiation in Cohort 2
Stanford is currently not accepting patients for this trial.
For more information, please contact Stefania U Chirita, 650-723-1423.
Stanford Investigators
View full details
-
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
Not Recruiting
More
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms
with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
Recruiting
More
Through this study, we hope to learn more about the mechanisms, which may contribute to
development and progression of head and neck cancer. The long-term goal of this study will be
to develop new strategies and drugs for the diagnosis and treatment of head and neck cancer.
Lead Sponsor
Stanford Investigators
View full details
-
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Not Recruiting
More
This randomized phase II trial studies the side effects and how well modestly reduced-dose
intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating
patients with oropharyngeal cancer that has spread to other places in the body (advanced).
Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. It is
not yet known whether IMRT is more effective with or without cisplatin in treating patients
with oropharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Not Recruiting
More
This randomized phase 3 trial studies how well modified Dakin's solution works in reducing
radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with
head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce
inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.
Radiation therapy in this study is regulatory medical care based on the patient's needs and
the radiation oncologist's judgment. It is not possible nor necessary to explicitly define
the dose or duration of treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amanda Simmons, 650-724-4606.
Lead Sponsor
Stanford Investigators
View full details
-
Treatment Outcomes and Quality of Life After IMRT Treatments of Head and Neck Cancers
Not Recruiting
More
The purpose of the research study is to evaluate effectiveness and the quality of life,
specifically the risk of dry mouth, after radiation treatment for head and neck cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 6504986184.
Lead Sponsor
Stanford Investigators
View full details
-
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Not Recruiting
More
The purpose of this research study is to test the safety and effectiveness of palifermin to
determine if weekly doses can be safely administered to reduce the incidence (occurrence of),
duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in
the mouth). Mucositis is a common side effect for patients receiving chemotherapy
(cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and
neck cancer (HNC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Rachel Freiberg, 6507254777.
Stanford Investigators
View full details
-
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Recruiting
More
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous
cell). Specialized radiation therapy that delivers a high dose of radiation directly to the
tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in
chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a
monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. The purpose of this study is to compare the usual treatment (radiation therapy with
cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy,
and using the usual treatment plus an immunotherapy drug, atezolizumab.
Stanford Investigators
View full details
-
Imaging and Biomarkers of Hypoxia in Solid Tumors
Not Recruiting
More
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Justin Carter, 650-725-4796.
Lead Sponsor
Stanford Investigators
- Quynh-Thu Le, MD
- Edward Graves
- John B. Sunwoo, MD
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- Heather Wakelee
- Amato J. Giaccia
- A. Dimitrios Colevas, MD
- Billy W Loo, Jr, MD PhD FASTRO FACR
- Edward J. Damrose, MD, FACS
- Michael J. Kaplan, MD
View full details
-
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Not Recruiting
More
There are two study questions we are asking in this randomized phase II/III trial based on a
blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally
advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard
concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if
there is no detectable EBV DNA in their plasma, then patients are randomized to either
standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still
detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and
fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high
energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin,
fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil
is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in
treating patients with nasopharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Not Recruiting
More
PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of
radiation therapy plus cisplatin in patients who have head and neck cancer that is not
related to the human papillomavirus (HPV).
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-725-7805.
Stanford Investigators
View full details
-
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
Not Recruiting
More
In patients with cancer of the head and neck and rectum, knowing the exact location of the
tumor is important for designing the radiation field to ensure delivery of high dose of
radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method
which is a combination of positron emission tomography (PET) and computed tomography (CT)
scan, has shown promise in helping the radiation oncologist in defining the exact location
and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of
this study is to determine if these imaging methods can be used in combination with the
standard radiation treatment planning procedure to improve the accuracy to targeting your
tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better
resolution, can be used to determine whether the tumor has spread to any part of the body
outside of the head and neck sites.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 6504986184.
Lead Sponsor
Stanford Investigators
View full details
-
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer
Not Recruiting
More
The main objective of this study is to determine the feasibility of optimizing the IMRT
treatment plan based on dosimeter measurements of mucosal radiation dose adjacent to the
dental fillings to reduce such dose to < 35 Gy without compromising tumor coverage and/or
increasing the dose to the remaining oral cavity or nearby parotid glands.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cato Chan, 650-724-4606.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Not Recruiting
More
This randomized phase III trial studies how well radiation therapy, paclitaxel, and
carboplatin with or without trastuzumab work in treating patients with esophageal cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of
tumor cells to grow and spread. It is not yet known whether giving radiation therapy and
combination chemotherapy together with or without trastuzumab is more effective in treating
esophageal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Not Recruiting
More
The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on
recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor
hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-723-1423.
Stanford Investigators
View full details
-
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Not Recruiting
More
A research study of a procedure to treating lung cancer with focused radiation called
Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the
effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR
based on tumor-specific factors.
While recent research has identified SABR as a promising method to increase local control
(LC) of lung cancer, further research has indicated that tumor volume is a prognostic factor,
with increased size/volume of tumor being associated with poorer outcomes. This study
explores if a volume-adapted strategy for the radiologic exposure (dose) will improve
efficacy in larger tumors (ie, > 10 cc).
This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study
of a specific drug or device.
Stanford is currently not accepting patients for this trial.
For more information, please contact Samantha Wong, 650-498-8495.
Lead Sponsor
Stanford Investigators
View full details
-
Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers
Not Recruiting
More
The purpose of the study is to identify a surrogate serum marker for tumor hypoxia in
patients with lung cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Rachel Freiberg, 6507254777.
Lead Sponsor
Stanford Investigators
View full details
-
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Not Recruiting
More
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA
concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients
with nasopharyngeal carcinoma (NPC).
2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these
tumors both in endemic and non-endemic areas.
3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for
both endemic and non-endemic patient populations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 650-498-6184.
Lead Sponsor
Stanford Investigators
View full details
-
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Not Recruiting
More
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck
cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the
efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression
(TTP) in this group of patients. In addition, we will determine the 2-year locoregional
control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these
patients. We will also evaluate the profile and frequency of late toxicity, specifically
mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with
locally advanced head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Brian Khong, 6507254777.
Stanford Investigators
View full details
-
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Radiation therapy uses high energy
x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with
radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well
they work when followed by cetuximab and two different doses of intensity-modulated radiation
therapy in treating patients with HPV-associated stage III or stage IV cancer of the
oropharynx that can be removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells.
Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Giving these treatments before surgery may
make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is
not yet known whether chemotherapy and radiation therapy are more effective when given with
or without panitumumab in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see
how well they work when given with or without panitumumab in treating patients with stage
IIIA non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Not Recruiting
More
To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD1839
in combination with cisplatin and radiation therapy in patients with local-regional recurrent
squamous cell cancer of the head and neck.
To study the effects of ZD1839 combined with either cisplatin or radiotherapy on signal
transduction pathway gene expression in tumor cells in patients with local-regional recurrent
squamous cell cancer of the head and neck using micro array analysis from tumor samples taken
at the time of relapse and during treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Priscilla Wong, 6507254777.
Lead Sponsor
Stanford Investigators
View full details
-
Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
Not Recruiting
More
The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy
with radiosurgery for locally advanced pancreas cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Stanford Cancer Clinical Trials Office, 6504987061.
Lead Sponsor
Stanford Investigators
View full details
-
Real-Time kV Imaging vs. Real-Time 3D Patient Surface Tracking for Head & Neck Cancer
Not Recruiting
More
To determine if a new optical system that can track a patient's movement during treatment can
be used to measure motion and allow for motion adjustments in order to decrease the amount of
healthy tissue that receives radiation without limiting our ability to cure cancers using
radiation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Brian Khong, 6507254777.
Lead Sponsor
Stanford Investigators
View full details
-
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells.
PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain
radiation therapy works in treating patients with brain metastases.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jacob Wynne, 6507238843.
Stanford Investigators
View full details